GlaxoSmithKline Pharmaceuticals block deals, bulk deals, insider trading and stake changes
NSE: GLAXOBSE: 500660Pharmaceuticals & BiotechnologyMid Cap
Formerly Glaxo (India)
Last close ₹2,404.70down ₹29.00 (1.19%)BSE ₹2,404.80
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,433.70.
52-week range of traded prices to 23 Oct 2026
₹2,088.10Low, 12 Jun 2026₹3,120.70High, 28 Aug 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹40,737 Cr221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 3 Aug 2026
- 38.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 13 May 2026
- 18.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.37%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 3 Aug 2026
- 50.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 3 Aug 2026
- 56.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 13 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 56,17458.6% delivered
GlaxoSmithKline Pharmaceuticals insider trading
All 2 disclosures on record. The company's own latest disclosure on record is from Mar 2017.Insider trading, all companies
Sep 2018
- BonusEach share became 2 on 11 Sep 2018. The lines below are on the share count before it.
Mar 2017
- Castleton Investment Ltd₹870 Cr31,92,238 sharesGave · Promoter Group · 30 Mar 2017 · Inter-se-Transfer · held 31,92,238 before
- GlaxoSmithKline Pte Ltd₹870 Cr31,92,238 sharesReceived · Promoters · 30 Mar 2017 · Inter-se-Transfer · stake 24.33% before, 28.10% after
Trades by the company's promoters, directors, key managers, employees and their relatives, as each disclosed them. Value is what the filer stated; the mode is shown where the shares moved off the market.
GlaxoSmithKline Pharmaceuticals stake sales and purchases
All 4 disclosures on record.
Dec 2019
- SoldLife Insurance Corporation Of India2.01% of the company34,02,936 sharesholds 6.00% after19 Dec 2019 · filed under the 2% rule · Open Market
- SoldLife Insuracne Corporation Ltd2.01% of the company34,02,936 sharesholds 5.99% after19 Dec 2019 · filed under the 2% rule · Open Market
Sep 2018
- BonusEach share became 2 on 11 Sep 2018. The lines below are on the share count before it.
Mar 2017
- AcquiredGlaxoSmithkline Pte Ltd · promoter3.77% of the company31,92,238 sharesholds 28.10% after30 Mar 2017 · filed under the 2% rule · Inter-se transfer
- SoldCastlet Investments Ltd · promoter3.77% of the company31,92,238 sharesholds none after30 Mar 2017 · filed under the 2% rule · Inter-se transfer
The 5% rule: an investor discloses on reaching 5% of the company. The 2% rule: a holder of 5% or more discloses each change of 2% or more, including one that takes it below 5%. A transfer exempt from an open offer, the offer to buy from every other shareholder that a large purchase otherwise brings, is disclosed too. Each line shows what its filing states, which can be a smaller change than its rule names.
GlaxoSmithKline Pharmaceuticals block deals and bulk deals
None in the last 12 months, since 23 Oct 2025.Today's bulk and block deals, all companies
ValueValue of a deal. The shares traded times the deal's price.Per cent of the companyPer cent of the company. The shares traded as a percentage of all the company's shares in issue on the day of the deal.
Monday 17 Oct 20224 firms · ₹13 Cr bought · ₹13 Cr soldNet nil
- SoldISHARES CORE EMERGING MARKETS MAURITIUS COBlock dealSold 80,615 at ₹1,378.650.05% of the company₹11 Cr
- BoughtISHARES CORE MSCI EMERGING MARKETS ETFBlock dealBought 80,615 at ₹1,378.650.05% of the company₹11 Cr
- SoldISHARES INDIA SC MAURITIUS COMPANYBlock dealSold 11,841 at ₹1,378.650.01% of the company₹1.63 Cr
- BoughtISHARES MSCI INDIA SMALL-CAP ETFBlock dealBought 11,841 at ₹1,378.650.01% of the company₹1.63 Cr
Tuesday 11 Oct 20224 firms · ₹12 Cr bought · ₹12 Cr soldNet nil
- SoldISHARES CORE EMERGING MARKETS MAURITIUS COBlock dealSold 77,734 at ₹1,393.450.05% of the company₹11 Cr
- BoughtISHARES CORE MSCI EMERGING MARKETS ETFBlock dealBought 77,734 at ₹1,393.450.05% of the company₹11 Cr
- SoldISHARES INDIA SC MAURITIUS COMPANYBlock dealSold 11,417 at ₹1,393.450.01% of the company₹1.59 Cr
- BoughtISHARES MSCI INDIA SMALL-CAP ETFBlock dealBought 11,417 at ₹1,393.450.01% of the company₹1.59 Cr
Monday 3 Oct 20224 firms · ₹13 Cr bought · ₹13 Cr soldNet nil
- SoldISHARES CORE EMERGING MARKETS MAURITIUS COBlock dealSold 77,439 at ₹1,424.400.05% of the company₹11 Cr
- BoughtISHARES CORE MSCI EMERGING MARKETS ETFBlock dealBought 77,439 at ₹1,424.400.05% of the company₹11 Cr
- SoldISHARES INDIA SC MAURITIUS COMPANYBlock dealSold 11,373 at ₹1,424.400.01% of the company₹1.62 Cr
- BoughtISHARES MSCI INDIA SMALL-CAP ETFBlock dealBought 11,373 at ₹1,424.400.01% of the company₹1.62 Cr
Monday 19 Sep 20224 firms · ₹12 Cr bought · ₹12 Cr soldNet nil
- SoldISHARES CORE EMERGING MARKETS MAURITIUS COBlock dealSold 72,154 at ₹1,431.750.04% of the company₹10 Cr
- BoughtISHARES CORE MSCI EMERGING MARKETS ETFBlock dealBought 72,154 at ₹1,431.750.04% of the company₹10 Cr
- SoldISHARES INDIA SC MAURITIUS COMPANYBlock dealSold 10,499 at ₹1,431.750.01% of the company₹1.50 Cr
- BoughtISHARES MSCI INDIA SMALL-CAP ETFBlock dealBought 10,499 at ₹1,431.750.01% of the company₹1.50 Cr
BonusEach share became 2 on 11 Sep 2018. The lines below are on the share count before it.
Tuesday 23 Feb 20162 firms · ₹22 Cr bought · ₹22 Cr soldNet nil
- SoldNEW INDIA INVESTMENT COMPANY MAURITIUS LIMITEDBlock dealSold 69,000 at ₹3,219.10₹22 Cr
- BoughtNEW INDIA INVESTMENT TRUST PLCBlock dealBought 69,000 at ₹3,219.10₹22 Cr
Friday 18 May 20072 firms · ₹126 Cr bought · ₹131 Cr soldNet sold ₹4.83 Cr
- SoldT ROWE PRICE INTERNATIONAL INCSold 10,87,076 at ₹1,207.00₹131 Cr
- BoughtHSBC INVESTMENTS HONG KONG LIMITEDBought 10,47,076 at ₹1,207.00₹126 Cr
Monday 24 Oct 20052 firms · ₹37 Cr bought · ₹37 Cr soldNet bought ₹0.05 Cr
- BoughtT. ROWE PRICE INTERNATIONAL INCBought 4,27,191 at ₹870.00₹37 Cr
- SoldMORGAN STANLEY INVESTMENT MANAGEMENT LTDSold 4,26,571 at ₹870.00₹37 Cr
A bulk deal is one client trading half a per cent or more of the shares in a day; a block deal is a large trade in the exchange's separate block window, its buyer and its seller each on a line of their own. A firm that bought and sold the shares the same day is on one line, with its net. All 13 deals on record from 4 Jan 2004.